Pipeline

Our development program focuses on new approaches to neurological diseases and disorders.

Our portfolio has a number of compounds with multiple potential indications and multiple targets. This is an ideal portfolio for innovative, experimental medicine techniques, including state-of-the-art imaging tools, to establish rapid proof-of-concept through small, smart clinical trials. This will allow us to find in a cost-effective and efficient manner the best indication for each compound and the best compound for each indication.

Please click in the compounds for further information

Compounds
SYN-114
Cognitive Disorders
SYN-115
Parkinson's
Drug Dependency
SYN-116
Acute pain
SYN-117
Drug Dependency
SYN-119
Drug Dependency

* Compounds that have entered Good Laboratory Practice (GLP) and toxicology studies as part of preparations for entry into man.

SYN-114

SYN-114 is an orally bioavailable, potent and selective small molecule antagonist of the 5-HT₆ receptor. 5-HT₆ receptors are expressed exclusively in the brain and in regions associated with memory function.

The molecule is active in a variety of preclinical models of cognition and executive function. SYN-114 facilitates memory consolidation and demonstrates effects consistent with enhanced cholinergic function.

SYN-114 is in phase 1.

Indication: Cognitive disorders

Partnership: Roche

SYN-115

SYN-115 is a potent and selective inhibitor of the A2A receptor, which modulates the production of dopamine, glutamine and serotonin in specific regions of the brain.

In preclinical models of Parkinson's disease, A2A inhibition has resulted in increased levels of dopamine, resulting in the reversal of motor deficits.

SYN-115 is in Phase 1.

Indication: Parkinson's and drug dependency

Partnership: Roche

SYN-116

SYN-116 is an orally bioavailable, potent and selective inhibitor of the IP-receptor, which is under evaluation for the treatment of mild to moderate acute and post-operative pain. Tissue injury results in the release of prostanoids - primarily PGE-2 and PGI-2 - that activate receptors on sensory neurons causing a painful sensation.

Selectively inhibiting the effect of PGI-2 has the potential to deliver analgesic efficacy at least comparable to the non-steroidal anti-inflammatory drugs (NSAIDs) but without the side-effects associated with the inhibition of PGE-2.

SYN-116 is in Phase 1.

Indication: Acute Pain

Partnership: Roche

SYN-117

SYN-117 is a potent, competitive, and selective dopamine β-hydroxylase inhibitor under investigation for the treatment of Parkinson's disease and drug dependency.

Dopamine β-hydroxylase is the main enzyme responsible for the conversion of dopamine into norepinephrine. The inhibition of this enzyme has been shown to raise dopamine levels in the CNS with the potential to alleviate the symptoms of Parkinson's. In addition, the modulation of dopamine has the potential for the treatment of drug dependency

The molecule is orally available and well tolerated in preclinical models and in the clinic, at doses significantly above the expected therapeutic range.

SYN-117 is in Phase 1.

Indication: Drug dependency

Partnership: Roche

SYN-119

SYN-119 potently and selectively enhances the activity of glutamate at the mGluR-1 receptor. The molecule is under evaluation for the treatment of drug dependency.

Certain drugs of abuse cause plasticity in regions of the brain associated with pleasure and reward.

In preclinical studies, SYN-119 has been shown to prevent or reverse these changes and so has the potential to modulate the addictive properties of drugs of abuse, facilitate withdrawal from these drugs and decrease relapse rates.

SYN-119 is in pre-clinical studies.

Indications: Drug dependency

Partnership: Roche